Possible genetic predictor for response to lithium augmentation in depressed patients

As in most fields of medicine, psychiatry researchers are working to identify specific types of patients, through their individual genetic variations, that may better benefit from particular drugs or combinations of drugs than other patients. A new study, published in Biological Psychiatry’s December 1st issue, investigated whether depressed patients with a particular genetic variation would better respond to the addition of lithium to their treatment regimen, as opposed to an antidepressant-only treatment.

Adli and colleagues recruited acutely depressed patients who were unresponsive to an antidepressant-only treatment, and augmented their therapy with lithium, the most common medication used to treat bipolar disorder. They then genotyped these patients for variations in the GSK3B gene. This gene codes for the enzyme glycogen synthase kinase 3-beta, which is inhibited by lithium.

Mazda Adli, M.D., corresponding author on the project, explains their findings: “[We] found that antidepressant non-responders with depression show a significantly better response to a subsequent lithium augmentation if they carry at least one C-allele as opposed those patients carrying two T-alleles, which is in line with the previous findings regarding this genetic polymorphism.” In other words, patients who carried a specific genetic variation, the C-allele, were more likely to get better with the addition of lithium to their treatment than patients with other variations of the GSK3B gene.

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments, “Over the past several years, preclinical studies have suggested that GSK3-beta was a key molecular switch related to the clinical effectiveness of lithium. This hypothesis is supported by this report from Adli et al. They find that variation in the GSK3-beta gene is related to lithium response in patients, further implicating GSK3-beta as a potential target for antidepressant treatment.”

Dr. Adli adds, “If replicable, the findings of this study could be an important step towards an individually tailored antidepressive treatment plan for patients with depression as well as for the identification of possible new drug targets.”

Source: Elsevier

Related stories:

Genetic roots of bipolar disorder revealed by first genome-wide study of illness
The likelihood of developing bipolar disorder depends in part on the combined, small effects of variations in many different genes in the brain, none of which is powerful enough to cause the disease by itself, a new study shows. However, targeting the enzyme produced by one of these genes could lead to development of new, more effective medications.
Genetic 'fingerprint' shown to predict liver cancer's return
Scientists have reached a critical milestone in the study of liver cancer that lays the groundwork for predicting the illness's path, whether toward cure or recurrence. By analyzing the tissue in and around liver tumors, an international research team has identified a kind of genetic "fingerprint" that can help predict if patients' cancers will return. The findings appear in the October 15 advance online edition of the New England Journal of Medicine and were made possible by a large-scale method for revealing genes' activity, which the researchers show can be applied to tissues that have been chemically preserved instead of frozen. This technical triumph promises to unlock biological information within millions of clinical samples previously intractable to genomic study.
Scientists close in on method to fight deadly childhood cancer
A multicenter team of researchers, including scientists from the University of Florida, has discovered a way to potentially block the growth of neuroblastoma, a type of cancer responsible for 15 percent of all cancer deaths in children.
New approach to genetic testing could halve deaths from inherited bowel cancer
Changing the approach to genetic screening for cancers in Australia could effectively halve deaths caused by an inherited form of bowel cancer, says a University of Melbourne expert.
Researchers continue to find genes for type 1 diabetes
Genetics researchers have identified two novel gene locations that raise the risk of type 1 diabetes. As they continue to reveal pieces of the complicated genetic puzzle for this disease, the researchers expect to improve predictive tests and devise preventive strategies.
AAT protein restores blood glucose in type 1 diabetes model
A protein made by the liver in response to inflammation and used to treat patients suffering from a genetic form of emphysema has been shown to restore blood glucose levels in a mouse model of Type 1 diabetes mellitus, according to a new study led by researchers at Beth Israel Deaconess Medical Center (BIDMC).
A breakthrough, then a surge, in stem cell research
Less than a year after a Wisconsin team helped discover a major alternative to human embryonic stem cells, the Madison scientists say more than 800 labs have begun using the approach, suggesting that many stem-cell researchers are starting to move beyond controversial embryonic sources for their work.
Landmark study unlocks stem cell, DNA secrets to speed therapies
In a groundbreaking study led by an eminent molecular biologist at Florida State University, researchers have discovered that as embryonic stem cells turn into different cell types, there are dramatic corresponding changes to the order in which DNA is replicated and reorganized.

News discussion:

Medicine & Health news